Qingdao Baheal Medical Inc. (known as “Baheal Medical”, Stock Code: 301015) was founded in 2005. Serving as the pharmaceutical industrialization platform that supports upstream innovation, Baheal Medical focuses on the development, manufacturing and commercialization of medical innovations, and effectively optimizing the medical practices through technological innovation.

Through our core technical capabilities in modern traditional Chinese medicine (TCM) and advanced controlled-release formulations, Baheal Medical has established a sophisticated R&D and production system for both TCM and chemical medicines. We have successfully launched a variety of innovative products with proprietary intellectual property rights, and consistently drive forward technological development and production for upstream medical innovations.

Leveraging our well-established commercialization capabilities and extensive nationwide sales and marketing network, Baheal Medical accelerates the adoption of high-quality medical and health products in clinical practices. It has incubated multiple leading brands in the field of bone health, liver disease and metabolic disorders, and has established a rich product matrix covering Over the Counter (OTC) and general health, OTX and prescription medicine, oncology drugs, as well as high-end medical devices to meet the various healthcare needs of the entire society.